Enlivex Therapeutics Ownership | Who Owns Enlivex Therapeutics?

Enlivex Therapeutics Ownership Summary

Enlivex Therapeutics is owned by 9.29% institutional investors, 78.36% insiders, and 12.34% retail investors. Ark investment management is the largest institutional shareholder, holding 1.38% of ENLV shares. ARK Israel Innovative Technology ETF is the top mutual fund, with 0.99% of its assets in Enlivex Therapeutics shares.

ENLV Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Enlivex Therapeutics	9.29%	78.36%	12.34%
Sector	Healthcare Stocks	244.59%	12.11%	-156.70%
Industry	Biotech Stocks	379.61%	11.70%	-291.31%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Ark investment management	628.31K	1.38%	$584.39K
Prelude capital management	225.74K	0.49%	$209.96K
Two sigma investments, lp	146.41K	0.32%	$136.18K
Ubs group	138.33K	0.30%	$128.65K
Renaissance	128.19K	0.28%	$119.23K
Jpmorgan chase	125.95K	0.28%	$113.35K
Goldman sachs group	102.09K	0.22%	$94.96K
Xtx topco	100.36K	0.22%	$93.35K
Morgan stanley	98.33K	0.22%	$91.46K
Geode capital management	80.56K	0.18%	$74.93K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Prelude capital management	225.74K	0.02%	$209.96K
Ark investment management	628.31K	0.00%	$584.39K
Xtx topco	100.36K	0.00%	$93.35K
Skyview investment advisors	10.00K	0.00%	$9.00K
Renaissance	128.19K	0.00%	$119.23K
Activest wealth management	1.00K	0.00%	$930.00
Red tortoise	150.00	0.00%	$140.00
Two sigma investments, lp	146.41K	0.00%	$136.18K
Bfsg	-	-	-
Spire wealth management	-	-	-

Top Buyers

Holder	Shares	% Assets	Change
Ark investment management	628.31K	0.00%	628.31K
Prelude capital management	225.74K	0.02%	225.74K
Jpmorgan chase	125.95K	-	123.83K
Ubs group	138.33K	-	103.34K
Goldman sachs group	102.09K	-	102.09K

Top Sellers

Holder	Shares	% Assets	Change
Diametric capital, lp	-	-	-1.48M
Armistice capital	-	-	-1.41M
Citizens financial group inc/ri	-	-	-231.42K
Renaissance	128.19K	0.00%	-185.44K
Hrt financial lp	-	-	-153.99K

New Positions

Holder	Shares	% Assets	Change	Value
Ark investment management	628.31K	0.00%	628.31K	$584.39K
Prelude capital management	225.74K	0.02%	225.74K	$209.96K
Goldman sachs group	102.09K	-	102.09K	$94.96K
Geode capital management	80.56K	-	80.56K	$74.93K
Caitong asset management	1.00	-	1.00	$1.00

Sold Out

Holder	Change
Sbi securities	-1.00
Qube research	-1.00
Global retirement partners	-11.00
Us bancorp \de\	-50.00
Raymond james financial	-57.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	27	-25.00%	4,247,263	16.71%	9	14.49%	16	-23.81%	7	16.67%
Mar 31, 2026	35	29.63%	3,508,719	165.29%	7	25.52%	20	33.33%	6	200.00%
Dec 31, 2025	10	-64.29%	590,338	-34.73%	2	17.08%	6	-50.00%	1	-80.00%
Sep 30, 2025	12	-40.00%	287,663	-87.72%	1	1.05%	2	-60.00%	1	-83.33%
Jun 30, 2025	22	-21.43%	2,557,493	-19.40%	11	5.56%	5	-44.44%	8	14.29%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
ARK Israel Innovative Technology ETF	2.38M	0.99%	-
Dolphin 90/10 IL	43.48K	0.20%	-
MTF TR TA-Growth	37.59K	0.17%	-1.46K
IBI Mehaka TA-Growth	13.30K	0.06%	-80.00
Fidelity Nasdaq Composite Index	129.86K	0.05%	-5.69K
Dolphin Flexible	7.42K	0.03%	-
Invesco NASDAQ Future Gen 200 ETF	66.82K	0.03%	-
I.B.I 90/10	5.75K	0.03%	-
Harel HTF TA All-Share IL	3.86K	0.02%	9.00
I.B.I Government + 10% IL	3.00K	0.01%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Oct 09, 2015	Murray Michael Anthony	former SVP - Operations	Sell	$156.76K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	-
2025 Q4	-	-
2024 Q2	-	-
2024 Q1	-	-
2023 Q4	-	-

ENLV Ownership FAQ

Who Owns Enlivex Therapeutics?

Enlivex Therapeutics shareholders are primarily institutional investors at 9.29%, followed by 78.36% insiders and 12.35% retail investors. The average institutional ownership in Enlivex Therapeutics's industry, Biotech Stocks , is 379.61%, which Enlivex Therapeutics falls below.

Who owns the most shares of Enlivex Therapeutics?

Enlivex Therapeutics’s largest shareholders are Ark investment management (628.31K shares, 1.38%), Prelude capital management (225.74K shares, 0.49%), and Two sigma investments, lp (146.41K shares, 0.32%). Together, they hold 2.19% of Enlivex Therapeutics’s total shares outstanding.

Does Blackrock own Enlivex Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Enlivex Therapeutics.

Who is Enlivex Therapeutics’s biggest shareholder by percentage of total assets invested?

Prelude capital management is Enlivex Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.02% of its assets in 225.74K Enlivex Therapeutics shares, valued at 209.96K$.

Who is the top mutual fund holder of Enlivex Therapeutics shares?

ARK Israel Innovative Technology ETF is the top mutual fund holder of Enlivex Therapeutics shares, with 0.99% of its total shares outstanding invested in 2.38M Enlivex Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools